CCL20 and melanoma: The analysis using the log-rank test demonstrated that melanoma patients with high CCL20 have an impaired PFS with a median of 3 months (95% CI: 2–6) compared to patients with a low CCL20 with a median of 10.5 months (95% CI: 6–26) (p = 0.0033) (Figure 1).